Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ) Stock Forecast — 2-Week Outlook

StockMap's current 2-week read on Jazz Pharmaceuticals plc Common Stock (Ireland) (JAZZ) is Neutral.

The composite score behind that read is +0.10, weighing +0.36 of bullish evidence against -0.59 bearish.

Jazz Pharmaceuticals plc Common Stock (Ireland) last closed at $218.42, -1.81% on the session.

Against the IVW growth benchmark the position is -2.61% over the forecast window.

The read is built from 15 underlying insights — 10 bullish and 5 bearish.

Agreement across those insights is 67%.

14 graded predictions for JAZZ so far. We publish our accuracy across thousands of stocks in the open, misses included — no per-stock hit rate is claimed on a small sample.

On the fundamentals StockMap ranks Jazz Pharmaceuticals plc Common Stock (Ireland) in the 61st percentile on valuation and the 82nd percentile on return on equity, where 100 is best.

Jazz Pharmaceuticals plc Common Stock (Ireland) is classified under Health Care / Pharmaceuticals, with a market capitalisation of $14.44B.

StockMap tracks Jazz Pharmaceuticals plc Common Stock (Ireland) as the 16th largest of the 151 companies it covers in the Pharmaceuticals industry, part of the Health Care sector.

Across that group the current two-week reads are 90 Neutral, 46 Moderate Underperform and 15 Moderate Outperform.

On that composite Jazz Pharmaceuticals plc Common Stock (Ireland) ranks 34th of 151 in the group, against a group median of -0.08.